Investor Relations
- Top
- Investor Relations
IR News
-
2026.09.16Product(製品情報)Marketing Approval for new specification of Ustekinumab Biosimilar - USTEKINUMAB BS 130mg intravenous infusion「F」-
-
2026.09.16Product(製品情報)Marketing Approval for new specification of Golimumab Biosimilar - GOLIMUMAB BS 50mg autoinjector for S.C. injection「F」-
-
2026.08.06Financial Results(決算資料)Supplemental Materials of FY9/26 3Q Consolidated Financial Results
